Ames, IA. May 25, 2022. Mazen, an animal health company developing novel oral vaccines,
announced today the closing of its Series A round of over $11M. The round was led by Fall Line
Capital and joined by all the Seed investors, including Next Level Ventures, Kent Corporation, Ag
Startup Engine, Ag Ventures Alliance, ISAV and Summit Ag. In addition, new investors,
AgFunder, 1330 Investments, Addison Laboratories, SLO Seeds Ventures and Cal Poly Ventures
also participated in the financing.

Vaccination of livestock prevents disease and decreases losses; however, injectable vaccination
can be costly and difficult to administer. Mazen offers a transformative vaccine technology
where the animals don’t even know they are being vaccinated. By administering the vaccine
with feed, we eliminate challenges associated with finding labor to administer injectable
vaccines and other issues such as broken needles in the animal or accidental vaccination of the
worker. Oral vaccines allow for cost effective disease prevention with improved animal
welfare.

“I am thrilled to have Fall Line Capital lead our Series A round. They believe in our experienced
team and transformational technology – and share our vision for aggressive growth”, said Jenny
Filbey, CEO of Mazen. “I am also delighted to have all our Seed investors continue to support
us both financially and in the community. We have a great group of investors.”

Mazen’s oral vaccines are produced via recombinant protein production in corn. The
technology platform leverages many years of breakthrough R&D led by John Howard, Mazen
Co-Founder and world-leading expert in recombinant protein production in plants. The
vaccines developed using this technology promise to be substantially more cost-effective and
convenient than traditional injectable vaccines for livestock and companion animals.
“Our investors are seeing the tremendous potential of the technology platform to deliver better
vaccines more efficiently,” said Filbey. “In fact, the technology can help achieve better animal
health through disease prevention – rather than treatment – and improve economics,
stewardship and sustainability.”

Mazen’s lead oral vaccine in development for the prevention of Porcine Epidemic Diarrhea
Virus (PEDV) is currently undergoing pivotal efficacy studies required for USDA approval. The
company is also scaling up commercial manufacture of the vaccine. Mazen’s pipeline has
advanced with ongoing proof-of-concept studies for coccidiosis in poultry and a third
proprietary product in development, also for poultry. The Series A funds will be used to
support launch of the PEDV product, development of pipeline products, addition of new
products to the pipeline, as well as adding new members to the team.

Eric O’Brien, Co-Founder and Managing Director of Fall Line Capital commented, “Mazen is at
the forefront of molecular farming technologies that leverage plants as natural production
factories for recombinant proteins and other high value molecules. This novel approach has
huge advantages in cost versus precision fermentation in expensive bioreactors or more
traditional vaccine production methods. We are excited to partner with Mazen as they pioneer
a whole new category of sustainable technologies in animal health.”

About Mazen Animal Health, Inc.
Mazen is an animal health company that is transforming preventive health by
commercializing orally delivered vaccines that offer several advantages to traditional injected
vaccines, including improved cost-effectiveness, safety, efficacy, and geographic applications.
For more information, visit mazenanimalhealth.com.